B. Riley Securities Reiterates Buy on Radiopharm Theranostics, Raises Price Target to $16
Benzinga Newsdesk 10 months ago
NewsPrice TargetReiterationAnalyst Ratings
B. Riley Securities analyst Yuan Zhi reiterates Radiopharm Theranostics (NASDAQ:RADX) with a Buy and raises the price target from $13 to $16.
B. Riley Securities analyst Yuan Zhi reiterates Radiopharm Theranostics (NASDAQ:RADX) with a Buy and raises the price target from $13 to $16.